SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Charlie Smith who wrote (1649)2/23/2000 12:00:00 PM
From: MGV  Read Replies (1) of 1754
 
This language from the Goldman Sachs note fairly parallels my view:

" Goldman, Sachs & Co. Investment Research

VISX, Incorporated

* * Aggressive Strategic Plan for Long-Term Growth * *

.... We view this bold strategy as a positive, but difficult earnings comparisons could be tough on the stock in the near-term.

EXPECTING A NEW WAVE IN THE LASER VISION CORRECTION MARKET. We continue to believe that the laser vision correction market is in its infancy. To date, the 1.6 million procedures performed have been primarily driven by patients who have myopia greater than 5 diopters with an early-adopter mentality. Moreover, most of the procedures performed thus far have been on patients who were not content with spectacles. With an expected reduction in laser surgery prices, we believe that price sensitive customers will enter the market. In addition, patients with less than 5 diopters of astigmatism - which account for 70%-80% of the nearsighted - who are currently comfortable with either spectacles or contact lenses may come into the market. This latter patient population is clearly the long-
term opportunity for VISX. With some 20 million people representing
potential candidates for laser surgery, the long-term dynamics of the
market appear to be extremely positive."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext